VACCINATION WITH TETANUS AND KLH TO ASSESS IMMUNE RESPONSES

接种破伤风和 KLH 疫苗以评估免疫反应

• 批准号: 7375861
• 负责人: Jeffrey Boone Miller
• 金额: $ 0.18万
• 依托单位: UNIVERSITY OF MINNESOTA
• 依托单位国家: 美国
• 财政年份: 2005
• 资助国家: 美国
• 起止时间: 2005-12-01 至 2006-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7375861
• 关键词: VACCINATION; TETANUS; KLH; ASSESS; IMMUNE

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. We have been striving toward a goal of using immunotherapy to prevent cancer relapse. One facet of this therapy is to stimulate specific immunity using cancer vaccines. However, tumors are heterogeneous and we hypothesize that the presence of cancer itself, cancer chemotherapy, or more aggressive therapies such as bone marrow transplants may be immunosuppressive. If this is true, cancer vaccines will not be effective until we can overcome this immunosuppression. We hypothesize that immune stimulating cytokines may be useful for this purpose. If one uses a cancer vaccine strategy and it fails, it is unclear whether failure is due to the cancer vaccine itself or a more generalized lack of responsiveness to any vaccine. To overcome this problem, in this protocol we will test two vaccines which are well characterized and very immunogenic. Tetanus toxoid has been used for decades and almost all individuals have had this. KLH, a foreign protein has been used since the early 1970's to assess immune responses. The major advantage of KLH is that it tests immune response to an antigen that individuals have not had prior exposure to (a so-called antigen). We will use tetanus and KLH to answer a very basic question of whether cancer patients have enough immune competence to respond to proteins which are 100% immunogenic in normal donors. In this protocol, we will stratify patients by their disease type, the amount of standard chemotherapy, and whether or not they will have undergone stem cell transplantation. The role of the GCRC in this protocol would be to administer both vaccines which are given intramuscularly and subcutaneously, to monitor toxicity, and to collect blood samples required for research tests to assess immune response.

本子项目是利用由NIH/NCRR资助的中心赠款提供的资源的众多研究子项目之一。子项目和研究者（PI）可能已经从另一个NIH来源获得了主要资金，因此可以在其他CRISP条目中表示。列出的机构是中心的，不一定是研究者的机构。我们一直在努力实现利用免疫疗法预防癌症复发的目标。这种疗法的一个方面是使用癌症疫苗刺激特异性免疫。然而，肿瘤是异质性的，我们假设癌症本身、癌症化疗或更积极的治疗（如骨髓移植）的存在可能会抑制免疫。如果这是真的，在我们能够克服这种免疫抑制之前，癌症疫苗将不会有效。我们假设免疫刺激细胞因子可能对这一目的有用。如果使用癌症疫苗策略而失败，则不清楚失败是由于癌症疫苗本身还是由于对任何疫苗缺乏反应性。为了克服这一问题，在本方案中，我们将测试两种具有良好特征且具有很强免疫原性的疫苗。破伤风类毒素已经使用了几十年，几乎所有人都有这种情况。KLH是一种外源蛋白，自20世纪70年代初以来一直用于评估免疫反应。KLH的主要优点是它测试了个体对以前没有接触过的抗原（所谓的抗原）的免疫反应。我们将使用破伤风和KLH来回答一个非常基本的问题，即癌症患者是否有足够的免疫能力对正常供体中100%免疫原性的蛋白质做出反应。在本方案中，我们将根据患者的疾病类型、标准化疗量以及是否接受干细胞移植对患者进行分层。GCRC在本议定书中的作用是管理肌肉注射和皮下注射两种疫苗，监测毒性，并收集研究试验所需的血液样本，以评估免疫反应。